Table 1:

Demographics and baseline characteristics

	Placebo plus axitinib	Dalantercept plus axitinib
	n=61	n=58
Sex
Male	35 (57%)	38 (66%)
Female	26 (43%)	20 (35%)
Median age in years (range)	59 (27–75)	63 (37–81)
Prior systemic therapies
1	39 (64%)	34 (59%)
≥2	22 (36%)	24 (41%)
Prior nephrectomy	52 (85%)	56 (97%)
ECOG status
0	31 (51%)	33 (57%)
1	30 (49%)	25 (43%)
MSK risk group
Favorable	33 (54%)	23 (40%)
Intermediate	26 (43%)	33 (57%)
Poor	2 (3%)	2 (3%)
IMDC risk group
Favorable	16 (26%)	11 (19%)
Intermediate	43 (71%)	45 (78%)
Poor	2 (3%)	2 (3%)

Data are from the all-treated set (all randomized patients who received study drug) and are n (%) unless otherwise noted. ECOG=Eastern Cooperative Oncology Group. IMDC=International Metastatic Renal Cancer Database Consortium. MSK=Memorial Sloan Kettering Cancer Center.